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Abstract
BACKGROUND—The Gynecologic Oncology Group conducted this phase II trial to estimate 
the anti-tumor activity of bevacizumab and to determine the nature and degree of toxicity in 
patients with recurrent sex cord-stromal tumors of the ovary.
METHODS—A prospective, multi-institutional cooperative group trial was performed in women 
with recurrent measurable ovarian stromal tumor. Patients were allowed to have unlimited prior 
therapy, excluding bevacizumab. Bevacizumab 15 mg/kg was administered intravenously on day 
one of every 21 day cycle until disease progression or adverse effects prohibited further treatment. 
The primary endpoint was response rate (RR). Inhibin A and B levels were measured prior to each 
cycle, and the values were examined in relation to response and progression.
RESULTS—Thirty-six patients were enrolled, all of whom were eligible and evaluable. Patients 
received a median of nine cycles of treatment (range, 2-37 cycles). Six patients (16.7%) had 
partial responses (90% CI: 7.5%, 30.3%), 28 patients (77.8%) had stable disease, and two patients 
(5.6%) had increasing disease. This met the criterion for declaring the regimen active. The median 
PFS was 9.3 months. The median OS has not been reached. Two grade 4 toxicities occurred: 
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hypertension and proteinuria; the most common grade 3 toxicities were hypertension (n=5) and 
pain (n=5). Inhibin A and B values were lower in patients who responded to treatment.
CONCLUSIONS—Bevacizumab has activity in the treatment of recurrent sex cord-stromal 
tumors of the ovary; toxicity is acceptable. Further investigation is warranted.
Keywords
Stromal ovarian tumors; bevacizumab
INTRODUCTION
Sex cord-stromal tumors (SCSTs) of the ovary are rare neoplasms, which account for less 
than 5% of all ovarian malignancies.1-3 This group of ovarian stromal tumors include the 
granulosa cell tumor, granulosa cell–theca cell tumor, Sertoli-Leydig cell tumor 
(androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-stromal 
tumor, and sex cord tumor with annular tubules. SCSTs tend to have an indolent course, 
compared to epithelial ovarian cancer, and can recur decades after their initial diagnosis and 
treatment. Unfortunately, these tumors are particularly resistant to chemotherapy, and 
treatment of recurrent disease is difficult, even with the use of surgery, radiotherapy, 
chemotherapy, and hormonal agents.4-6
The investigation of novel therapeutic approaches is warranted based on the limited efficacy 
of these standard treatment options. The tumor biology of SCSTs suggests the importance of 
angiogenesis in tumor development and progression. These tumors are known to be 
vascular, and can present with hemoperitoneum in up to 30% of patients.5 Lymph node 
metastases are extremely rare yet distant metastasis is common, further suggesting that 
hematogenous spread predominates and that angiogenesis may play an important role in 
these tumors.7-8 A recent case series of eight patients treated at a single institution suggested 
that bevacizumab is active in the setting of recurrent disease, but this included multiple 
regimens with and without cytotoxic therapy and was retrospective in nature. This report 
also suggested that VEGF overexpression and microvessel density were associated with 
worse outcome and a more aggressive phenotype, though the sample size was too small to 
calculate statistical significance.8 Together, these observations suggest that antiangiogenic 
agents, such as bevacizumab, may have a role in treating women with SCSTs. However, the 
body of literature surrounding these characteristics is limited, and a prospective study of any 
antiangiogenic agent in SCSTs has not been previously performed.
Since SCSTs are uncommon, clinical trials exploring therapeutic options have been limited. 
Performing these trials in a cooperative group setting such as the Gynecologic Oncology 
Group (GOG) allows for rapid accrual and evaluation. The primary objective of our phase II 
study was to estimate the anti-tumor activity of bevacizumab by assessing the frequency of 
objective response in patients with recurrent sex cord-stromal tumors of the ovary with 
measurable disease. The secondary objectives were to examine the overall survival (OS) and 
progression-free survival (PFS), and to determine the nature and degree of toxicity in these 
patients. A translational research objective was to determine the association of inhibin A and 
inhibin B with response to treatment.
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Eligible patients had a histologically confirmed diagnosis of recurrent ovarian stromal 
tumor, including granulosa cell tumor, granulosa cell-theca cell tumor, Sertoli-Leydig cell 
tumor (androblastoma), steroid (lipid) cell tumor, gynandroblastoma, unclassified sex cord-
stromal tumor, or sex cord tumor with annular tubules. Since some patients had experienced 
multiple episodes of recurrent disease prior to enrolling in this protocol, any histologic 
confirmation of recurrent SCST was considered sufficient for enrollment, and a repeat 
biopsy was not mandated. Central pathologic review confirmed the diagnosis of ovarian 
SCST. Patients with measurable disease according to Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria, Version 1.1, defined as at least one lesion that could be 
accurately measured in at least one dimension (longest dimension to be recorded), with each 
target lesion ≥20 mm when measured by conventional techniques, including palpation, plain 
radiograph, computerized tomography, or magnetic resonance imaging, or ≥10 mm when 
measured by spiral CT were eligible. Other eligibility criteria included a GOG performance 
status of 0, 1, or 2; adequate hematologic, renal, and hepatic function; and patients of 
childbearing potential with a negative pregnancy test must have agreed to practice an 
effective means of birth control. There were no restrictions on prior therapy, but patients 
could not have previously received bevacizumab.
Study Design
This GOG prospective, multi-institutional phase II trial was designed to estimate the anti-
tumor activity of bevacizumab by assessing the frequency of objective response, to examine 
the OS and PFS, and to determine the nature and degree of toxicity in these patients. Patients 
were to receive bevacizumab intravenously at a dose of 15 mg/kg every 21 days until 
disease progression or prohibitive toxicity. Bevacizumab was provided by the manufacturer, 
free of charge to the patient. Each 21 day period was considered 1 cycle. Serum inhibin A 
and B levels were measured every cycle of treatment. The study received local institutional 
review board approval at participating institutions, and all patients gave written informed 
consent according to institutional and federal guidelines before treatment.
Treatment Plan and Dose Modification
Toxicity was monitored with history, physical examination, and laboratory assessment 
before each treatment cycle, with adverse events defined and graded according to National 
Cancer Institute Common Toxicity Criteria version 3.0. Guidelines were established for dose 
delay and dose reduction for hematologic and non hematologic toxicity.
Patient Assessment
Activity of bevacizumab was assessed according to RECIST, either by clinical evaluation, 
computed tomography or magnetic resonance imaging at baseline, and before every other 
cycle for the measurement of target lesions, the classification of clinical response, and the 
determination of disease progression. Therapy was discontinued for disease progression, 
unacceptable toxicity, receipt of other anticancer therapy, or voluntary withdrawal.
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The primary objective of the study evaluated the efficacy of the study agent as assessed by 
objective tumor responses. Tumor response rate (RR) was used as the primary endpoint, 
rather than survival or PFS, for two reasons. First, there are limited prior data serving as a 
reference for PFS and OS in this disease setting, so these endpoints cannot be used to define 
activity of the agent. Secondly, an objective response is one meaningful way to assess 
antitumor activity. By setting a low threshold for tumor response (5%), this enables us to 
have reasonable probability (alpha of 10%) of ruling out truly inactive agents for further 
investigation.
The targeted accrual for the first stage was 19 patients but was allowed to deviate for 
administrative purposes. With 24 eligible and evaluable patients, more than one patient 
responding was required to go to second stage. The cumulative targeted accrual for the 
second stage was 34 but was allowed to deviate. With 36 eligible and evaluable patients, 
more than three patients with responses were required to declare the agent sufficiently active 
to warrant further evaluation.
The design aimed to limit the expected probabilities of type I and II errors to no more than 
10% under the assumed accrual ranges of 15 to 22 (stage 1) and 30 to 37 (cumulatively after 
stage 2). Using the method of Chen and Ng9, if the true RR was 5%, the study design 
limited the average probability (across the accrual range) of incorrectly designating the 
treatment as active to 10%. On the other hand, if the true RR was 20%, then the average 
probability of correctly classifying the treatment as active was 90%.
Kaplan-Meier estimates were used for PFS and OS. Exact confidence intervals (CIs) were 
used for binary parameters. The primary endpoint was RR (RR), evaluated in a two-stage 
design (with power of 0.90 for a RR of 20% and with alpha of 0.10 for RR of 5%). The 
reverse Kaplan-Meier method was used to calculate median follow-up.10
Inhibin A and inhibin B values were measured every cycle of treatment. A small number of 
inhibin A and inhibin B results were determined to be less than the cutoff; in these cases, the 
cutoff value was used for calculation. A number of inhibin B values were determined to be 
above the cutoff; in these cases, the cutoff value was used for analysis. Results were similar 
when these values were excluded from the analysis and when 0.5 times the lower cutoff and 
1.5 times the upper cutoff were used. Analyses of timepoint-specific values were done using 
medians and rank-based (nonparametric) methods. Medians of the 25th and 75th percentiles 
were used for summary statistics, and Wilcoxon rank sum tests were used to compare 
groups. Summary statistics and comparison of inhibin A and inhibin B values between 
responders and nonresponders are presented for only the first 4 cycles, because the number 
of patients with available data decreased from 32 patients with available data in cycle 1 to 
22 patients with available data in cycle 5. Joint models of both longitudinal inhibin values 
and progression-free survival (PFS) were also random effects models to model the inhibin 
values over time and proportional hazards models. Natural log inhibin values were used in 
these joint models.11
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From September 2008 through January 2011, 36 patients were enrolled, all of whom were 
eligible and evaluable. Patient characteristics of the study group are listed in Table 1. The 
GOG performance status was zero in 30 patients (83.3%) and one in six patients (16.7%). Of 
the 36 patients, 32 patients had a granulosa cell tumor (88.9%) and four patients had an 
unclassified sex cord-stromal tumor (11.1%). When the referring pathology diagnosis was 
compared with central pathology review, 33 of 36 cases (91.7%) were concordant. All 3 
patients for whom a different diagnosis was rendered by central pathology review were 
ultimately determined to have SCST, unclassified; these patients had initial diagnoses of 
granulosa cell tumor, Sertoli-Leydig cell tumor, and unknown, respectively. Of the 36 
patients, 33 patients (91.7%) had received prior chemotherapy, with a median of two prior 
regimens. Six patients had previously received radiotherapy (16.7%). None had received 
prior immunotherapy.
Treatment Administration
A total of 491 cycles of bevacizumab were administered, with a median of nine cycles of 
treatment per patient (range, 2-50 cycles, with the latter patient still on study).
Activity of bevacizumab
The activity of bevacizumab was analyzed in the 36 enrolled patients. Six patients had a 
partial response (16.7%; 90% CI, 7.5 to 30.3%), 28 patients had confirmed stable disease 
(77.8%), and two patients had increasing disease (5.6%). This RR met the criteria to declare 
the agent active. For the six patients who had partial responses, the median (25th - 75th 
percentiles) time to response was 8.2 (1.5 – 14.4) months, and the duration of response was 
18.6 (17.9 – 27.2) months. The median PFS was 9.3 months, and the median OS was not 
reached with a median followup of 32.5 months. The graphs of the Kaplan-Meier estimates 
of PFS and OS for the study population are shown in Figures 1 and 2.
As of December 2012, one patient remains on study after 50 cycles and with a partial 
response. Five patients remain alive without progression, 23 patients remain alive with 
progression, and eight patients have died: five due to disease, one due to treatment and 
disease, and two whose cause of death is pending.
Toxicity
As shown in Table 3, the safety of bevacizumab in all 36 patients was analyzed 
descriptively; events listed had been reported as at least possibly related to study drug. 
Grade 3 adverse events at least possibly related to bevacizumab included hypertension (n = 
5), pain (n = 5), and dyspnea, dyspnea+hypoxia, leukopenia, anemia, hypophosphatemia, 
proteinuria, coagulation, tinnitus, constipation and distension, fatigue, genitourinary/renal, 
hematoma, and syncope (n =1 each). Two grade 4 toxicities were observed: hypertension 
and proteinuria. The cardiac events were all related to hypertension, and the gastrointestinal 
event was an incarcerated hernia requiring emergent surgery. There were no gastrointestinal 
perforations. Four (11%) of the 36 patients came off study due to toxicity.
Brown et al. Page 5






















Inhibin A and Inhibin B
The median inhibin A value was 12 pg/mL at cycle 1 (baseline) and decreased slightly 
across the following three cycles to 12, 11, and 9 pg/mL. Inhibin A values were lower 
(although not statistically significantly, p=0.100) at baseline in responders versus non-
responders (medians of 6 pg/mL versus 15 pg/mL), and values in cycles 2, 3, and 4 were 
statistically significantly lower in patients that responded to treatment (median value of 2 
pg/mL) than in those who did not respond to treatment (median values of 30, 32, and 34 
pg/mL in cycles 2, 3, and 4, respectively) (Table 3). The median inhibin B value was 217 
pg/mL at cycle 1 (baseline) and decreased after treatment to 168, 169, and 169 pg/mL in 
cycles 2, 3, and 4, respectively. Inhibin B values were lower (although not statistically 
significantly, p=0.100) at baseline in responders versus non-responders (medians of 61 
pg/mL versus 308 pg/mL), and values in cycles 2, 3, and 4 were statistically significantly 
lower in patients that responded to treatment than in those who did not respond to treatment, 
and this was significant in cycles 2, 3, and 4 (Table 4). Results from the joint models of 
inhibin and PFS showed a nonstatistically signficant increased hazard of progression or 
death with increasing levels of inhibin A or inhibin B. For inhibin A, a one unit increase in 
the log inhibin A levels was associated with a hazard rate [HR] (95% CI) of 1.15 (0.96, 
1.38), p=0.129. For inhibin B, a one unit increase in the log inhibin B levels was associated 
with a HR (95% CI) of 1.09 (0.89, 1.33), p=0.424.
DISCUSSION
Bevacizumab administered as a single agent appears to be active and have acceptable 
toxicity in women with recurrent sex cord-stromal tumors of the ovary. This represents a 
significant advance in women with this rare disease in whom effective treatment options are 
quite limited and disease is often chemorefractory. Previously, the only options for systemic 
therapy included BEP, paclitaxel and carboplatin, and hormonal therapy4-5, 12-13. The ability 
to use bevacizumab as an effective means of controlling tumor progression is a meaningful 
addition to the short list of therapeutics available for these patients.
Pre-treatment inhibin A and inhibin B values were lower in patients who responded to 
therapy than in those who did not respond to therapy, although the differences were not 
statistically signficant (p=0.100). These values were found to be significantly lower 
postbaseline in patients who responded to bevacizumab than in patients who did not 
respond. These data suggest that further investigation into the inhibins’ potential prognostic 
and predictive relevance is warranted. Patients with high inhibin levels may have a more 
aggressive tumor type that will not respond to bevacizumab or other treatments, while 
patients with lower levels may be good candidates for certain treatments, as seen in this 
study. The conclusions drawn from these pilot data, however, need to be carefully 
considered since this is a small study, and further investigation is required before this is used 
as a guideline. It is also interesting that the trend of inhibin A and B levels followed the 
pattern of disease response, though this did not reach statistical significance. The hazard 
level associated with progression or death was higher with increasing inhibin A than 
increasing inhibin B, but neither trend reached significance; therefore this does not suggest 
that inhibin A is a better marker than inhibin B. It may be that the high percentage of stable 
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disease in this study precluded the changing levels of inhibin A and B reaching significance. 
As has been suggested, inhibin A and B may represent effective markers for following 
progression or response of disease on therapy, like CA-125 in epithelial ovarian cancer, but 
further evaluation as to the accuracy of correlation needs to be done.14-15 The use of high 
inhibin levels to triage patients away from bevacizumab, however, is a new concept that 
bears further investigation.
The histology of most of these patients was granulosa cell tumor, which reflects the relative 
frequency of this histologic subtype. While one must be careful in generalizing the results of 
this report to all patients with stromal ovarian tumors, it is likely that the results of this trial 
do apply to other histologic subtypes of stromal ovarian tumors, based on historical findings 
of similar responses among patients with various subtypes of stromal tumors3-4, 6, 12-13.
In this study, tumor RR was used as the primary endpoint, rather than survival or PFS, for 
several reasons. RR represents a clinically meaningful decision criterion for determining 
whether the therapy was effective or ineffective when deciding on continuation into the 
second stage of the study and when deciding on the success of the overall study. There are 
limited prior data in this patient population, which precluded the use of PFS or OS to judge 
the activity of the agent in this disease setting. Instead, objective response was used, and a 
relatively low threshold for tumor response (5%) enabled us to have reasonable probability 
(alpha of 10%) of ruling out truly inactive agents for further investigation. A prior GOG trial 
in previously treated patients with stromal tumors evaluated bleomycin, etoposide and 
cisplatin.12 The observed RR in that trial was 37.5% (9/24). However, that study required 
patients to be chemo naíve, whereas the current study allows patients to have any number of 
prior chemo regimens. It is important to note that no biologic agent has been prospectively 
studied in patients with SCSTs before this trial. Therefore, the RR was chosen as the 
primary endpoint, as it is the more clinically useful parameter to gauge activity of 
bevacizumab in this specific disease setting.
Since the rationale for this study was to identify an antivascular agent for future combination 
with cytotoxic chemotherapy and not simply utility as monotherapy, the criteria to declare 
this agent interesting based on an objective RR was set lower than for identifying an agent 
with monotherapy activity. Therefore, the null hypothesis was set at 5%; if bevacizumab 
yielded a RR of 5% or less, it would not be of interest to evaluate further in combination 
with other agents. Therefore, although the RR is less than the conventionally accepted rate 
of 20% to declare an agent active, bevacizumab met the conditions of this trial to declare it 
as an active agent.
A substantial percentage of patients experienced stable disease. To determine stable disease 
in this clinical trial required imaging documenting stable disease followed by confirmed 
imaging after two additional courses. Since courses were three weeks apart, this implies at 
least 12 weeks of stable disease. The possibility exists that the indolent nature of this disease 
might lead to a suggestion that the drug was responsible for stable disease when in fact 
tumor biology was responsible for the large percentage of patients who experienced stable 
disease. In the absence of a randomized trial comparing therapy with a placebo arm, 
however, this is impossible to determine with certainty. The eventual progression or death 
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from disease of 29 patients, and the median PFS of 9.3 months, however, suggests that this 
disease does grow and not simply remain dormant, leading to our opinion that the substantial 
rate of stable disease in this trial truly represents drug effect. Previous reports on “active” 
agents for stromal ovarian tumors report a PFS of 14-19.6 months in patients with recurrent, 
measurable disease4, 12-13 The long median time to progression in those patients with stable 
disease, as well as a PFS which is comparable to that described in the published literature for 
“active” compounds for stromal ovarian tumors4, 12-13 leads to the conclusion that the 
response rate, PFS, and time to progression do represent real drug effects rather than 
indolent tumor behavior.
The toxicity profile described in this study is typical for bevacizumab, and represents 
findings that would be expected. Bevacizumab appears to be tolerable in patients with 
recurrent SCSTs.
To conduct meaningful clinical trials in rare tumors outside of a cooperative group setting is 
difficult. The short accrual time required to complete this trial highlights the feasibility of 
efficiently completing clinical trials in patients with rare tumors in a cooperative group 
setting. Furthermore, the finding of activity in this tumor that has historically been relatively 
chemoresistant underscores the importance of allocating resources to perform cooperative 
group trials in rare tumors, as this substantially moves the field forward. An additional 
strength of running trials in the cooperative group setting is the ability to assemble historical 
data sets against which future trial results can be judged; this trial is the first step in doing so 
for SCSTs of the ovary.
The results of this clinical trial indicate that bevacizumab has activity in the treatment of 
recurrent SCSTs of the ovary, and that toxicity is acceptable in this treatment setting. Inhibin 
A and inhibin B appear to be associated with response to therapy. Further investigation is 
warranted, and combination therapy with a cytotoxic, targeted, or hormonal agent may be an 
upcoming investigation in this cooperative group setting. In addition, a randomized phase II 
study comparing paclitaxel and carboplatin with bleomycin, etoposide, and cisplatin in 
patients with newly diagnosed advanced and recurrent chemo naive stromal ovarian tumors 
is currently underway within this cooperative group, further refining optimal therapy for 
patients with these rare tumors.
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Kaplan-Meier estimates of PFS
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Kaplan-Meier estimates of OS
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 30-39 1 2.8
 40-49 8 22.2
 50-59 12 33.3
 60-69 11 30.6
 70-79 4 11.1
Race
 Unspecified 2 5.6
 Asian 1 2.8
 African-American 3 8.3
 White 30 83.3
Ethnicity
 Hispanic 2 5.6
 Non-Hispanic 30 83.3
 Unspecified 4 11.1
Prior Chemotherapy
 0 3 8.3
 1 12 33.3
 2 14 38.9
 3 4 11.1
 4 2 5.6
 6 1 2.8
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Table 2
Adverse Events by Number of Episodes
AE Category 0 1 2 3 4 5 Total
Leukopenia 32 2 1 1 0 0 36
Thrombocytopenia 28 8 0 0 0 0 36
Anemia 21 7 7 1 0 0 36
Other Hematologic 33 2 1 0 0 0 36
Allergy/Immunology 23 11 2 0 0 0 36
Auditory/Ear 29 0 6 1 0 0 36
Cardiac 15 6 9 5 1 0 36
Coagulation 35 0 0 1 0 0 36
Constitutional 12 10 13 1 0 0 36
Dermatologic 17 14 4 1 0 0 36
Endocrine 33 2 1 0 0 0 36
Gastrointestinal 6 10 15 5 0 0 36
Genitourinary/Renal 29 5 1 1 0 0 36
Hemorrhage 17 18 0 1 0 0 36
Infection 23 0 11 2 0 0 36
Lymphatics 31 4 1 0 0 0 36
Metabolic 13 10 8 3 2 0 36
Musculoskeletal 30 5 1 0 0 0 36
Neurosensory 21 13 1 1 0 0 36
Other Neurological 22 12 1 1 0 0 36
Ocular/Visual 30 6 0 0 0 0 36
Pain 1 11 16 8 0 0 36
Pulmonary 12 20 1 3 0 0 36
Sexual/Reproductive 32 4 0 0 0 0 36
Syndromes 35 1 0 0 0 0 36
Vascular 35 0 1 0 0 0 36
Death, Not CTC coded 35 0 0 0 0 1 36


















































































































































































































































































































































































































































































































































































































Cancer. Author manuscript; available in PMC 2015 February 01.
